Prediction of risk for Type 2 Diabetes development.
BelDIA PRE is an easy to use screening test device for patients, clinics and physians. By determination of fasting plasma concentration of intact proinsulin, the test describes development of type 2 diabetes mellitus even up to one years prior to glucose elevation. It is designed as a point-of-care device to provide immediate results.
The early test is working with a lateral-flow based technology similar to a pregnancy test. The result is provided in a qualitative way and is either “positive” or “negative”. One drop of blood capillary blood (10 µl) is needed, e.g. obtained by pricking the fingertip.